Patents by Inventor Naama David

Naama David has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MIR-21 promoter driven targeted cancer therapy
    Patent number: 9044506
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: June 2, 2015
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
  • MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY
    Publication number: 20130310446
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 21, 2013
    Applicant: Ramot at Tel Aviv University, Ltd.
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
  • MIR-21 promoter driven targeted cancer therapy
    Patent number: 8492133
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: July 23, 2013
    Assignee: Ramot at Tel Aviv University, Ltd.
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David
  • MIR-21 PROMOTER DRIVEN TARGETED CANCER THERAPY
    Publication number: 20120065251
    Abstract: The invention provides a nucleic acid construct comprising a promoter sequence derived from microRNA-21 (miR-21) linked to a nucleic acid sequence encoding an anti-cancer agent, an example of which is a toxin. The constructs of the invention are particularly useful for treating tumors expressing miR-21.
    Type: Application
    Filed: January 19, 2010
    Publication date: March 15, 2012
    Inventors: Rina Rosin-Arbesfeld, Ella Sklan, Alona Zilberberg, Naama David